Low-Molecular-Weight Heparin (LMWH) is a type of anticoagulant medication similar to unfractionated heparin that works by enhancing antithrombin III activity. LMWH is clinically indicated for preventing and treating venous thromboembolism, deep vein thrombosis, coronary syndromes, and pulmonary embolism. Monitoring helps to maintain optimal LMWH levels for preventing, treating thromboembolic events and surgical prophylaxis.

References:

• Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS One. 2015 January 27;10(1):e0116835. doi: 10.1371/journal.pone.0116835. Accessed on Jan 31st,2024.
• Babin JL, Traylor KL, Witt DM. Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. Semin Thromb Hemost. 2017 April;43(3):261-269. doi: 10.1055/s-0036-1581129. Accessed on Jan 31st,2024.
• Data on File: PureLab DOS V5, November 10^th, 2023.